Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026170 | 0.83 | HRH3 (0.40) | HRH3NAMPTROCK2ROCK1CARM1 | |
| SCHEMBL20129353 | 0.82 | HRH3 (0.39) | HRH3NAMPTROCK2ROCK1MEN1 | |
| SCHEMBL21472222 | 0.81 | HRH3 (0.38) | HRH3NAMPTROCK2ROCK1MEN1 | |
| SCHEMBL23560035 | 0.80 | HRH3 (0.49) | HRH3NAMPTROCK2ROCK1CARM1 | |
| SCHEMBL20443206 | 0.79 | HRH3 (0.37) | HRH3NAMPTROCK2ROCK1MEN1 | |
| SCHEMBL18592313 | 0.79 | HRH3 (0.37) | HRH3NAMPTROCK2ROCK1MEN1 | |
| SCHEMBL23134534 | 0.77 | HRH3 (0.48) | HRH3NAMPTMEN1KMT2APIK3CD | |
| SCHEMBL23945451 | 0.76 | HRH3 (0.41) | HRH3NAMPTMEN1KMT2APIK3CD | |
| SCHEMBL24608232 | 0.76 | HRH3 (0.45) | HRH3NAMPTROCK2ROCK1CARM1 | |
| SCHEMBL24607658 | 0.75 | HRH3 (0.40) | HRH3NAMPTMEN1KMT2APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | HRH3 3763/4885NAMPT 869/4885ROCK2 621/4885 |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | HRH3 3945/4885NAMPT 2021/4885ROCK2 2175/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | HRH3 3161/4885NAMPT 4018/4885ROCK2 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.